Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 260

1.

Loss to follow-up: A significant barrier in the treatment cascade with direct-acting therapies.

Darvishian M, Wong S, Binka M, Yu A, Ramji A, Yoshida EM, Wong J, Rossi C, Butt ZA, Bartlett S, Pearce ME, Samji H, Cook D, Alvarez M, Chong M, Tyndall M, Krajden M, Janjua NZ.

J Viral Hepat. 2019 Oct 30. doi: 10.1111/jvh.13228. [Epub ahead of print]

PMID:
31664755
2.

Eliminating Structural Barriers: The Impact of Unrestricted Access on Hepatitis C Treatment Uptake among People Living with HIV.

Saeed S, Strumpf E, Moodie EEM, Wong L, Cox J, Walmsley S, Tyndall M, Cooper C, Conway B, Hull M, Martel-Laferriere V, Gill J, Wong A, Vachon ML, Klein MB; Canadian Co-Infection Cohort Study Investigators.

Clin Infect Dis. 2019 Aug 28. pii: ciz833. doi: 10.1093/cid/ciz833. [Epub ahead of print]

PMID:
31504327
3.

The population level care cascade for hepatitis C in British Columbia, Canada as of 2018: Impact of direct acting antivirals.

Bartlett SR, Yu A, Chapinal N, Rossi C, Butt Z, Wong S, Darvishian M, Gilbert M, Wong J, Binka M, Alvarez M, Tyndall M, Krajden M, Janjua NZ.

Liver Int. 2019 Dec;39(12):2261-2272. doi: 10.1111/liv.14227. Epub 2019 Sep 20.

PMID:
31444846
4.

Sustained virological response from interferon-based hepatitis C regimens is associated with reduced risk of extrahepatic manifestations.

Rossi C, Jeong D, Wong S, McKee G, Butt ZA, Buxton J, Wong J, Darvishian M, Bartlett S, Samji H, Yu A, Binka M, Alvarez M, Adu PA, Tyndall M, Krajden M, Janjua NZ; BC Hepatitis Testers Cohort Team.

J Hepatol. 2019 Dec;71(6):1116-1125. doi: 10.1016/j.jhep.2019.07.021. Epub 2019 Aug 6.

PMID:
31433302
5.

The Consensus Hepatitis C Cascade of Care: Standardized Reporting to Monitor Progress Toward Elimination.

Safreed-Harmon K, Blach S, Aleman S, Bollerup S, Cooke G, Dalgard O, Dillon JF, Dore GJ, Duberg AS, Grebely J, Boe Kielland K, Midgard H, Porter K, Razavi H, Tyndall M, Weis N, Lazarus JV.

Clin Infect Dis. 2019 Nov 27;69(12):2218-2227. doi: 10.1093/cid/ciz714.

PMID:
31352481
6.

What is killing people with hepatitis C virus infection? Analysis of a population-based cohort in Canada.

Krajden M, Cook DA, Wong S, Yu A, Butt ZA, Rossi C, Darvishian M, Alvarez M, Buxton JA, Tyndall M, Janjua NZ.

Int J Drug Policy. 2019 Oct;72:114-122. doi: 10.1016/j.drugpo.2019.06.003. Epub 2019 Jun 20.

PMID:
31229445
7.

Syndemic Characterization of HCV, HBV, and HIV Co-infections in a Large Population Based Cohort Study.

McKee G, Butt ZA, Wong S, Salway T, Gilbert M, Wong J, Alvarez M, Chapinal N, Darvishian M, Tyndall MW, Krajden M, Janjua NZ.

EClinicalMedicine. 2018 Nov 5;4-5:99-108. doi: 10.1016/j.eclinm.2018.10.006. eCollection 2018 Oct-Nov.

8.

Modelling the combined impact of interventions in averting deaths during a synthetic-opioid overdose epidemic.

Irvine MA, Kuo M, Buxton JA, Balshaw R, Otterstatter M, Macdougall L, Milloy MJ, Bharmal A, Henry B, Tyndall M, Coombs D, Gilbert M.

Addiction. 2019 Sep;114(9):1602-1613. doi: 10.1111/add.14664. Epub 2019 Jun 28.

PMID:
31166621
9.

Effectiveness of Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in People Who Inject Drugs and/or Those in Opioid Agonist Therapy.

Janjua NZ, Darvishian M, Wong S, Yu A, Rossi C, Ramji A, Yoshida EM, Butt ZA, Samji H, Chong M, Chapinal N, Cook D, Alvarez M, Tyndall M, Krajden M; British Columbia Hepatitis Testers Cohort Team.

Hepatol Commun. 2019 Jan 10;3(4):478-492. doi: 10.1002/hep4.1307. eCollection 2019 Apr.

10.

Characteristics of Gay, Bisexual and Other Men Who Have Sex With Men With Multiple Diagnoses of Infectious Syphilis in British Columbia, Canada, 2005-2014.

Konrad S, Mak DB, Grennan T, Zakher B, Brownrigg B, Ogilvie G, Morshed M, Tyndall M, Gilbert M, Krajden M, Wong J.

Sex Transm Dis. 2019 Jul;46(7):423-428. doi: 10.1097/OLQ.0000000000000995.

PMID:
30870310
11.

Variation in hepatitis C virus treatment uptake between Canadian centres in the era of direct-acting antivirals.

Nitulescu R, Young J, Saeed S, Cooper C, Cox J, Martel-Laferriere V, Hull M, Walmsley S, Tyndall M, Wong A, Klein MB; Canadian Co-Infection Cohort Study.

Int J Drug Policy. 2019 Mar;65:41-49. doi: 10.1016/j.drugpo.2018.08.012. Epub 2018 Dec 26.

PMID:
30594080
12.

The opioid death crisis in Canada: crucial lessons for public health.

Fischer B, Pang M, Tyndall M.

Lancet Public Health. 2019 Feb;4(2):e81-e82. doi: 10.1016/S2468-2667(18)30232-9. Epub 2018 Dec 20. No abstract available.

13.

Applying core theory and spatial analysis to identify hepatitis C virus infection "core areas" in British Columbia, Canada.

Butt ZA, Mak S, Gesink D, Gilbert M, Wong J, Yu A, Wong S, Alvarez M, Chong M, Buxton J, Tyndall M, Krajden M, Janjua NZ.

J Viral Hepat. 2019 Mar;26(3):373-383. doi: 10.1111/jvh.13043. Epub 2018 Dec 11.

PMID:
30447122
14.

Effect of opioid-substitution therapy and mental health counseling on HIV risk among hepatitis C-infected individuals.

Butt ZA, Shrestha N, Gesink D, Murti M, Buxton JA, Gilbert M, Balshaw RF, Wong S, Kuo M, Wong J, Yu A, Alvarez M, Samji H, Roth D, Consolacion T, Hull MW, Ogilvie G, Tyndall MW, Krajden M, Janjua NZ.

Clin Epidemiol. 2018 Aug 31;10:1127-1145. doi: 10.2147/CLEP.S173449. eCollection 2018.

15.

Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in a large population-based cohort.

Rossi C, Butt ZA, Wong S, Buxton JA, Islam N, Yu A, Darvishian M, Gilbert M, Wong J, Chapinal N, Binka M, Alvarez M, Tyndall MW, Krajden M, Janjua NZ; BC Hepatitis Testers Cohort Team.

J Hepatol. 2018 Nov;69(5):1007-1014. doi: 10.1016/j.jhep.2018.07.025. Epub 2018 Aug 22.

PMID:
30142429
16.

Estimating the impact of early hepatitis C virus clearance on hepatocellular carcinoma risk.

Darvishian M, Janjua NZ, Chong M, Cook D, Samji H, Butt ZA, Yu A, Alvarez M, Yoshida E, Ramji A, Wong J, Woods R, Tyndall M, Krajden M.

J Viral Hepat. 2018 Dec;25(12):1481-1492. doi: 10.1111/jvh.12977. Epub 2018 Aug 28.

PMID:
30047609
17.

Hepatitis C Testing, Status and Treatment among Marginalized People Who Use Drugs in an Inner City Setting: An Observational Cohort Study.

Boucher LM, Bayoumi AM, Mark AE, Cooper C, Martin A, Marshall Z, Boyd R, Oickle P, Diliso N, Pineau D, Renaud B, LeBlanc S, Tyndall M, Lee OM, Kendall CE.

Subst Use Misuse. 2019;54(1):18-30. doi: 10.1080/10826084.2018.1485699. Epub 2018 Jun 22.

PMID:
29932800
18.

At-a-glance - Impact of drug overdose-related deaths on life expectancy at birth in British Columbia.

Ye X, Sutherland J, Henry B, Tyndall M, Kendall PRW.

Health Promot Chronic Dis Prev Can. 2018 Jun;38(6):248-251. doi: 10.24095/hpcdp.38.6.05. English, French. Erratum in: Health Promot Chronic Dis Prev Can. 2019 Feb;39(2):64.

19.

Distribution of take-home opioid antagonist kits during a synthetic opioid epidemic in British Columbia, Canada: a modelling study.

Irvine MA, Buxton JA, Otterstatter M, Balshaw R, Gustafson R, Tyndall M, Kendall P, Kerr T, Gilbert M, Coombs D.

Lancet Public Health. 2018 May;3(5):e218-e225. doi: 10.1016/S2468-2667(18)30044-6. Epub 2018 Apr 18.

20.

Differing profiles of people diagnosed with acute and chronic hepatitis B virus infection in British Columbia, Canada.

Binka M, Butt ZA, Wong S, Chong M, Buxton JA, Chapinal N, Yu A, Alvarez M, Darvishian M, Wong J, McGowan G, Torban M, Gilbert M, Tyndall M, Krajden M, Janjua NZ.

World J Gastroenterol. 2018 Mar 21;24(11):1216-1227. doi: 10.3748/wjg.v24.i11.1216.

21.

Identifying injection drug use and estimating population size of people who inject drugs using healthcare administrative datasets.

Janjua NZ, Islam N, Kuo M, Yu A, Wong S, Butt ZA, Gilbert M, Buxton J, Chapinal N, Samji H, Chong M, Alvarez M, Wong J, Tyndall MW, Krajden M; BC Hepatitis Testers Cohort Team.

Int J Drug Policy. 2018 May;55:31-39. doi: 10.1016/j.drugpo.2018.02.001. Epub 2018 Feb 23.

PMID:
29482150
22.

Management and Point-of-Care for Tobacco Dependence (PROMPT): a feasibility mixed methods community-based participatory action research project in Ottawa, Canada.

Pakhale S, Kaur T, Charron C, Florence K, Rose T, Jama S, Boyd R, Haddad J, Alvarez G, Tyndall M.

BMJ Open. 2018 Jan 25;8(1):e018416. doi: 10.1136/bmjopen-2017-018416.

23.

An emergency response to the opioid overdose crisis in Canada: a regulated opioid distribution program.

Tyndall M.

CMAJ. 2018 Jan 15;190(2):E35-E36. doi: 10.1503/cmaj.171060. No abstract available.

24.

Routes of administration for cannabis use - basic prevalence and related health outcomes: A scoping review and synthesis.

Russell C, Rueda S, Room R, Tyndall M, Fischer B.

Int J Drug Policy. 2018 Feb;52:87-96. doi: 10.1016/j.drugpo.2017.11.008. Epub 2017 Dec 22. Review.

PMID:
29277082
25.

Hepatitis C cross-genotype immunity and implications for vaccine development.

Islam N, Krajden M, Shoveller J, Gustafson P, Gilbert M, Wong J, Tyndall MW, Janjua NZ; The BC-HTC Team.

Sci Rep. 2017 Sep 26;7(1):12326. doi: 10.1038/s41598-017-10190-8.

26.

A syndemic approach to assess the effect of substance use and social disparities on the evolution of HIV/HCV infections in British Columbia.

Butt ZA, Shrestha N, Wong S, Kuo M, Gesink D, Gilbert M, Wong J, Yu A, Alvarez M, Samji H, Buxton JA, Johnston JC, Cook VJ, Roth D, Consolacion T, Murti M, Hottes TS, Ogilvie G, Balshaw R, Tyndall MW, Krajden M, Janjua NZ; BC Hepatitis Testers Cohort.

PLoS One. 2017 Aug 22;12(8):e0183609. doi: 10.1371/journal.pone.0183609. eCollection 2017.

27.

Late hepatitis B and C diagnosis in relation to disease decompensation and hepatocellular carcinoma development.

Samji H, Yu A, Kuo M, Alavi M, Woods R, Alvarez M, Dore GJ, Tyndall M, Krajden M, Janjua NZ; BC Hepatitis Testers Cohort Team.

J Hepatol. 2017 Nov;67(5):909-917. doi: 10.1016/j.jhep.2017.06.025. Epub 2017 Jul 4.

PMID:
28684103
28.

Erratum to: A cohort study examining emergency department visits and hospital admissions among people who use drugs in Ottawa, Canada.

Kendall CE, Boucher LM, Mark AE, Martin A, Marshall Z, Boyd R, Oickle P, Diliso N, Pineau D, Renaud B, Rose T, LeBlanc S, Tyndall M, Lee OM, Bayoumi AM.

Harm Reduct J. 2017 Jul 3;14(1):42. doi: 10.1186/s12954-017-0169-7. No abstract available.

29.

A cohort study examining emergency department visits and hospital admissions among people who use drugs in Ottawa, Canada.

Kendall CE, Boucher LM, Mark AE, Martin A, Marshall Z, Boyd R, Oickle P, Diliso N, Pineau D, Renaud B, Rose T, LeBlanc S, Tyndall M, Lee OM, Bayoumi AM.

Harm Reduct J. 2017 May 12;14(1):16. doi: 10.1186/s12954-017-0143-4. Erratum in: Harm Reduct J. 2017 Jul 3;14 (1):42.

30.

Expanding conceptualizations of harm reduction: results from a qualitative community-based participatory research study with people who inject drugs.

Boucher LM, Marshall Z, Martin A, Larose-Hébert K, Flynn JV, Lalonde C, Pineau D, Bigelow J, Rose T, Chase R, Boyd R, Tyndall M, Kendall C.

Harm Reduct J. 2017 May 12;14(1):18. doi: 10.1186/s12954-017-0145-2.

31.

Incidence, risk factors, and prevention of hepatitis C reinfection: a population-based cohort study.

Islam N, Krajden M, Shoveller J, Gustafson P, Gilbert M, Buxton JA, Wong J, Tyndall MW, Janjua NZ; British Columbia Hepatitis Testers Cohort (BC-HTC) team.

Lancet Gastroenterol Hepatol. 2017 Mar;2(3):200-210. doi: 10.1016/S2468-1253(16)30182-0. Epub 2016 Dec 23. Erratum in: Lancet Gastroenterol Hepatol. 2017 Mar;2(3):e2.

PMID:
28404135
32.

Use of GetCheckedOnline, a Comprehensive Web-based Testing Service for Sexually Transmitted and Blood-Borne Infections.

Gilbert M, Salway T, Haag D, Fairley CK, Wong J, Grennan T, Uddin Z, Buchner CS, Wong T, Krajden M, Tyndall M, Shoveller J, Ogilvie G.

J Med Internet Res. 2017 Mar 20;19(3):e81. doi: 10.2196/jmir.7097.

33.

Shift in disparities in hepatitis C treatment from interferon to DAA era: A population-based cohort study.

Janjua NZ, Islam N, Wong J, Yoshida EM, Ramji A, Samji H, Butt ZA, Chong M, Cook D, Alvarez M, Darvishian M, Tyndall M, Krajden M.

J Viral Hepat. 2017 Aug;24(8):624-630. doi: 10.1111/jvh.12684. Epub 2017 Feb 20.

PMID:
28130810
34.

Cocaine/crack use is not associated with fibrosis progression measured by AST-to-Platelet Ratio Index in HIV-HCV co-infected patients: a cohort study.

Martel-Laferrière V, Nitulescu R, Cox J, Cooper C, Tyndall M, Rouleau D, Walmsley S, Wong L, Klein MB; Canadian Co-infection Cohort Study Investigators.

BMC Infect Dis. 2017 Jan 17;17(1):80. doi: 10.1186/s12879-017-2196-0.

35.

Uptake of Community-Based Peer Administered HIV Point-of-Care Testing: Findings from the PROUD Study.

Lazarus L, Patel S, Shaw A, Leblanc S, Lalonde C, Hladio M, Mandryk K, Horvath C, Petrcich W, Kendall C, Tyndall MW; Proud Community Advisory Committee.

PLoS One. 2016 Dec 2;11(12):e0166942. doi: 10.1371/journal.pone.0166942. eCollection 2016.

36.

Role of primary T-cell immunodeficiency and hepatitis B coinfection on spontaneous clearance of hepatitis C: The BC Hepatitis Testers Cohort.

Islam N, Krajden M, Gilbert M, Gustafson P, Yu A, Kuo M, Chong M, Alvarez M, Wong J, Tyndall MW, Janjua NZ.

J Viral Hepat. 2017 May;24(5):421-429. doi: 10.1111/jvh.12650. Epub 2016 Nov 25.

PMID:
27885757
37.

Effective Canadian policy to reduce harms from prescription opioids: learning from past failures.

Fischer B, Rehm J, Tyndall M.

CMAJ. 2016 Dec 6;188(17-18):1240-1244. doi: 10.1503/cmaj.160356. Epub 2016 Nov 7. No abstract available.

38.

Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.

Janjua NZ, Chong M, Kuo M, Woods R, Wong J, Yoshida EM, Sherman M, Butt ZA, Samji H, Cook D, Yu A, Alvarez M, Tyndall M, Krajden M.

J Hepatol. 2017 Mar;66(3):504-513. doi: 10.1016/j.jhep.2016.10.028. Epub 2016 Nov 4.

PMID:
27818234
39.

The Population Level Cascade of Care for Hepatitis C in British Columbia, Canada: The BC Hepatitis Testers Cohort (BC-HTC).

Janjua NZ, Kuo M, Yu A, Alvarez M, Wong S, Cook D, Wong J, Grebely J, Butt ZA, Samji H, Ramji A, Tyndall M, Krajden M.

EBioMedicine. 2016 Oct;12:189-195. doi: 10.1016/j.ebiom.2016.08.035. Epub 2016 Aug 25.

40.

A Comparison of Web and Telephone Responses From a National HIV and AIDS Survey.

Jones MK, Calzavara L, Allman D, Worthington CA, Tyndall M, Iveniuk J.

JMIR Public Health Surveill. 2016 Jul 29;2(2):e37. doi: 10.2196/publichealth.5184.

41.

Twin epidemics of new and prevalent hepatitis C infections in Canada: BC Hepatitis Testers Cohort.

Janjua NZ, Yu A, Kuo M, Alvarez M, Cook D, Wong J, Tyndall MW, Krajden M.

BMC Infect Dis. 2016 Jul 19;16:334. doi: 10.1186/s12879-016-1683-z.

42.

Thrombin generation assay in untreated whole human blood.

Modestino A, Tyndall M, Yu J, Lefkowitz RB, Schmid-Schönbein GW, Heller MJ.

Electrophoresis. 2016 Aug;37(15-16):2248-56. doi: 10.1002/elps.201600061.

PMID:
27271700
43.
44.

Assessing Hepatitis C Burden and Treatment Effectiveness through the British Columbia Hepatitis Testers Cohort (BC-HTC): Design and Characteristics of Linked and Unlinked Participants.

Janjua NZ, Kuo M, Chong M, Yu A, Alvarez M, Cook D, Armour R, Aiken C, Li K, Mussavi Rizi SA, Woods R, Godfrey D, Wong J, Gilbert M, Tyndall MW, Krajden M.

PLoS One. 2016 Mar 8;11(3):e0150176. doi: 10.1371/journal.pone.0150176. eCollection 2016.

45.

Treatment of prescription opioid disorders in Canada: looking at the 'other epidemic'?

Fischer B, Kurdyak P, Goldner E, Tyndall M, Rehm J.

Subst Abuse Treat Prev Policy. 2016 Mar 8;11:12. doi: 10.1186/s13011-016-0055-4.

46.

Substance Use and Related Harms among Aboriginal People in Canada: A Comprehensive Review.

Firestone M, Tyndall M, Fischer B.

J Health Care Poor Underserved. 2015 Nov;26(4):1110-31. doi: 10.1353/hpu.2015.0108. Review.

PMID:
26548667
47.

Risk environments facing potential users of a supervised injection site in Ottawa, Canada.

Shaw A, Lazarus L, Pantalone T, LeBlanc S, Lin D, Stanley D, Chepesiuk C, Patel S, Tyndall M; PROUD Community Advisory Committee.

Harm Reduct J. 2015 Oct 22;12:49. doi: 10.1186/s12954-015-0083-9.

48.

Cannabis vaping and public health--some comments on relevance and implications.

Fischer B, Russell C, Tyndall MW.

Addiction. 2015 Nov;110(11):1705-6. doi: 10.1111/add.13064.

PMID:
26471151
49.

Planning for the Next Global Pandemic.

Ross AG, Crowe SM, Tyndall MW.

Int J Infect Dis. 2015 Sep;38:89-94. doi: 10.1016/j.ijid.2015.07.016. Epub 2015 Aug 4.

50.

Misplaced advocacy: What does better hepatitis C treatment really mean?

Tyndall M.

CMAJ. 2015 Oct 20;187(15):1111-1112. doi: 10.1503/cmaj.150612. Epub 2015 Aug 4. No abstract available.

Supplemental Content

Loading ...
Support Center